Biogen Inc Cmn (BIIB) 254.93 $BIIB Juno (JUNO) Suffers

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 2:11 PM

Biogen Inc Cmn (BIIB) 254.93 $BIIB

Juno (JUNO) Suffers Setback, Pivotal Study on Clinical Hold
Arpita Dutt - Zacks Investment Research - Fri Jul 08, 7:44AM CDT
Juno's (JUNO) shares were down in pre-market trading with the FDA placing its pivotal study on clinical hold.
BLUE: 49.98 (+1.23), BIIB: 254.93 (+3.63), KITE: 48.55 (+0.02), JUNO: 27.96 (+0.15)

Stock Market News for July 07, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jul 07, 9:10AM CDT
Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.
MDVN: 62.73 (+0.63), BIIB: 254.93 (+3.63), VRTX: 90.39 (+1.43), GILD: 87.13 (+0.58), UNH: 140.79 (-0.48), MRK: 59.66 (+0.31), ALXN: 126.17 (+1.75), XOM: 94.16 (+0.62), CVX: 105.82 (+1.05), REGN: 378.69 (+0.34), CELG: 104.45 (-0.58)

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.73% Rise
Comtex SmarTrend(R) - Wed Jul 06, 12:22PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $240.71 to a high of $246.83. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $246.54 on volume of 854,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 254.93 (+3.63)

Biogen and AbbVie's Once-Monthly ZINBRYTA(TM) (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
BusinessWire - Tue Jul 05, 7:00AM CDT
--- Targeted Mechanism of Action of ZINBRYTA Did Not Cause Broad, Prolonged Depletion of Studied Immune Cell Types -
BIIB: 254.93 (+3.63), ABBV: 64.64 (+0.48)

Brexit Broke the Stock Market — But One Sector Remains a “Buy”
Greg Guenthner - Daily Reckoning - Thu Jun 23, 8:55AM CDT
This post Brexit Broke the Stock Market — But One Sector Remains a “Buy” appeared first on Daily Reckoning . We have to do our best to tune out the insanity and hope that the market gives us some direction. Today, Greg...
BIIB: 254.93 (+3.63)

Watch for Biogen Idec to Potentially Rebound After Falling 1.26% Yesterday
Comtex SmarTrend(R) - Tue Jun 21, 12:27PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $234.04 to a high of $238.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $236.54 on volume of 769,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 254.93 (+3.63)

Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology
BusinessWire - Tue Jun 21, 10:00AM CDT
Biogen (NASDAQ: BIIB) announced today the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, 2016. He will report to George A. Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team. Dr. McKenzie was promoted from his previous position as senior vice president of Global Biologics Manufacturing and Technical Operations.
BIIB: 254.93 (+3.63)

Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016
BusinessWire - Mon Jun 20, 3:01PM CDT
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the financial markets open.
BIIB: 254.93 (+3.63)

Stock Market News for June 16, 2016
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 9:10AM CDT
Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year
AGN: 240.80 (+0.21), BIIB: 254.93 (+3.63), MDT: 88.80 (+0.44), ALXN: 126.17 (+1.75), XOM: 94.16 (+0.62), BMY: 75.75 (+0.47), CVX: 105.82 (+1.05)

Biotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
PR Newswire - Tue Jun 14, 6:35AM CDT
On Monday, June 13, 2016, the NASDAQ Composite ended the trading session at 4,848.44, down 0.94%; the Dow Jones Industrial Average edged 0.74% lower, to finish at 17,732.48; and the S&P 500 closed at 2,079.06, down 0.81%. Stock-Callers.com has initiated coverage on the following equities: PTC Therapeutics Inc. (NASDAQ: PTCT), Biogen Inc. (NASDAQ: BIIB), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), and VIVUS Inc. (NASDAQ: VVUS). Learn more about these stocks by accessing their free trade alerts at:
PGNX: 5.50 (+0.03), BIIB: 254.93 (+3.63), VVUS: 1.16 (-0.02), PTCT: 7.59 (+0.06)

The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 254.93 (+3.63), BMRN: 89.46 (-2.03), ALXN: 126.17 (+1.75), IBB: 272.82 (+1.69), REGN: 378.69 (+0.34)

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 254.93 (+3.63), BMRN: 89.46 (-2.03), SRPT: 21.99 (-0.63), ALXN: 126.17 (+1.75), IBB: 272.82 (+1.69), REGN: 378.69 (+0.34)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 5.69 (+0.07), BIIB: 254.93 (+3.63), IDRA: 1.67 (-0.01), RTRX: 18.60 (-0.05), ACOR: 25.99 (-0.22)

New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio
BusinessWire - Thu Jun 09, 6:08AM CDT
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI(R) (etanercept) and FLIXABI(R) (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8-11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
BIIB: 254.93 (+3.63)

Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 254.93 (+3.63), SRPT: 21.99 (-0.63), ALXN: 126.17 (+1.75), AMGN: 161.13 (+0.03), ABBV: 64.63 (+0.47), REGN: 378.69 (+0.34), CELG: 104.45 (-0.58)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 5.69 (+0.07), BIIB: 254.93 (+3.63), IDRA: 1.67 (-0.01), RTRX: 18.60 (-0.05), LGND: 126.70 (+0.84), ACOR: 25.99 (-0.22)

Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar
Greg Guenthner - Daily Reckoning - Wed Jun 08, 8:29AM CDT
This post Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar appeared first on Daily Reckoning . Nineteen measly points. That’s all that separates the S&P 500 from topping its all-time closing highs. But not all...
BIIB: 254.93 (+3.63)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM’s Signal Card: A Wallet Tracker for All

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Purina Institute Highlights Nutritional Science at WSAVA 2026

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Cala Launches Game-Changer Wearable for Tremor Relief

Breaking New Ground in Neuromodulation Medical tech's on a roll, and Cala Health just hopped on the fast track with their latest launch—the Cala kIQ Plus System. This bad boy is aiming to offer relief for those grappling with hand tremors, thanks to its FDA clearance and a host of new features. It's the first of its kind, combining multiple therapy modes with an...

Skandia's Soundproofing Kit Expands to Brazil's Skies

Soundproofing Takes Off in Brazil Skandia has just pulled off a neat trick, earning the nod from Brazil's National Civil Aviation Agency (ANAC) for their King Air soundproofing kit. That means quieter skies ahead for operators of the King Air 200 and 300 series in Brazil. This is no small feat, folks; it's like finally getting that coveted backstage pass after years of...

Cure Blindness Project's 770K Screenings for World Sight Day

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Community Banks Missing $106B Lending Opportunity?

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Dentistry.One Achieves HITRUST i1, Boosts Cybertrust

HITRUST i1 Certification: The Gold Standard in Security For a world increasingly reliant on digital infrastructure, cybersecurity certification is no longer just a badge of honor; it's a cornerstone of trust. Dentistry.One nailed this down by bagging that coveted HITRUST i1 certification. When folks talk about securing data, HITRUST might as well be speaking gospel. We're...

NYSE Texas Redefines the U.S. Capital Markets Landscape

NYSE Texas: Carving a Niche The notion of 'Y'all Street' might seem like a gimmick, but NYSE Texas is pushing a serious agenda with its newly released white paper, 'NYSE Texas and the Reshaping of U.S. Capital Markets.' This is no small feat. Texas is already housing 235 NYSE-listed companies, boasting a colossal combined worth of $4.8 trillion. With 130 of these firms...

Pushing for National Liver Cancer Awareness in 2026

The Urgency of Liver Cancer Awareness Death doesn’t wait, does it? When liver cancer is the villain in question, every moment becomes precious because this beast doesn’t roar until it’s too late. Here we are in 2026, staring at nearly 31,000 annual deaths in the U.S. alone. But hope flickers with a new congressional resolution aiming to slap a bright spotlight on...

Karoo Health Leaps Forward with New CCO Breton

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...